Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Genomize
Istanbul, Istanbul Province, Turkeygenomize.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Genomize’s SEQ Platform processes next-generation sequencing (NGS) data from raw reads to clinical reports. It enables accurate ACMG classification for confident variant interpretation and supports real-time genotype/phenotype database management. The platform has processed nearly 80,000 samples across multiple countries and institutions.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Bioinformatics Platform
- Industry
- Molecular Diagnostics
02
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.
Beyond the preview
Go deeper on Genomize.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genomize.